{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:08:00Z","timestamp":1782486480402,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd008907.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000}}],"reference-count":30,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008907.pub3","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T01:21:31Z","timestamp":1508894491000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eslicarbazepine acetate add-on for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2018","author":[{"given":"Xian-Chao","family":"Chang","sequence":"first","affiliation":[{"name":"Ningbo No. 2 Hospital; Department of Neurology; 41 Xibei Street Ningbo Zhejiang China 315010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Second People\u2019s Hospital of Hefei City; Department of Rehabilitation Medicine; No. 246 Heping Road Hefei Anhui China 230011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University; Division of Preventive Medicine; University Town Wenzhou Zhejiang China 325000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qin","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wenzhou Medical University; Department of Neurology; 2 Fuxue Lane Lucheng District Wenzhou China 325000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ke","family":"Hong","sequence":"additional","affiliation":[{"name":"Ningbo No. 2 Hospital; Department of Neurology; 41 Xibei Street Ningbo Zhejiang China 315010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Yuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wenzhou Medical University; Department of Neurology; 2 Fuxue Lane Lucheng District Wenzhou China 325000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"key":"10.1002\/14651858.CD008907.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Sperling MR Abou-Khalil B Harvey J Rogin JB Biraben A Galimberti CA Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial Epilepsia 2015 244 53","DOI":"10.1111\/epi.12894"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s13312-013-0284-9","article-title":"Newer anti-epileptic drugs","volume":"50","author":"Aneja","year":"2013","journal-title":"Indian Pediatrics"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.yebeh.2015.09.018","article-title":"Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate","volume":"53","author":"Cramer Joyce","year":"2015","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0008|cit8","first-page":"129","article-title":"[Exalief as a newer antiepileptic drug for adjunctive therapy of refractory partial-onset seizures]","volume":"114","author":"Ermolenko","year":"2014","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jad.2014.11.013","article-title":"Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I","volume":"174","author":"Grunze","year":"2015","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC neurology"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40263-014-0182-2","article-title":"Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures","volume":"28","author":"Keating Gillian","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0012|cit12","first-page":"122, Abstract n","article-title":"Design of a phase III, double-dummy, active-controlled, multi-national non-inferiority monotherapy trial of eslicarbazepine acetate versus controlled-release carbamazepine In adults with partial-onset seizures [abstract]","volume":"53","author":"Moreira","year":"2012","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling Michael","year":"2015","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1212\/WNL.0000000000002497","article-title":"Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies","volume":"86","author":"Sperling Michael","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2147\/DDDT.S57409","article-title":"Clinical utility of eslicarbazepine: current evidence","volume":"9","author":"Zaccara","year":"2015","journal-title":"Drug design, development & therapy"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0016|cit16","unstructured":"NCT00988429 Efficacy and safety study of eslicarbazepine acetate (BIA 2 093) as adjunctive therapy for refractory partial seizures in children https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00988429"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4(1)","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0018|cit18","unstructured":"Brozek J Oxman A Sch\u00fcnemann H GRADEpro Version 3.6 for Windows 2004"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0019|cit19","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011), The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0020|cit20","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD008907.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/0023210-200923010-00005","article-title":"Eslicarbazepine acetate","volume":"23","author":"McCormack","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0022|cit22","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"issue":"2","key":"10.1002\/14651858.CD008907.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1517\/13543780802635107","article-title":"Eslicarbazepine acetate: a new option for the treatment of focal epilepsy","volume":"18","author":"Mestre","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0024|cit24","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD008907.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00019052-200304000-00008","article-title":"The epidemiology of epilepsy revisited","volume":"16","author":"Sander","year":"2003","journal-title":"Current Opinion in Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008907.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1474-4422(08)70108-X","article-title":"Intractable epilepsy: management and therapeutic alternatives","volume":"7","author":"Schuele","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0027|cit27","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008907.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/WNL.49.2.333","article-title":"Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs","volume":"49(2)","author":"Walker","year":"1997","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD008907.pub3-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008907","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","author":"Chang","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008907.pub3-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008907.pub2","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","author":"Chang","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008907.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008907.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:25:09Z","timestamp":1628547909000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008907.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008907.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008907.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,25]]}}}